Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics Previous close 52.95
Open 52.95
Day range 52.95 53.00
52-week range 43.76 54.45
Off day high −0.09%
Off 52-week high −2.75%
Volume 20.70K
Avg. volume (3M) 340.87K
Market cap 11.01B
EPS (TTM) 2.38
Forward P/E 14.08
P/E ratio (TTM) 22.25
Dividend yield 2.68% (1.42)
Beta (5Y) 0.50
Shares outstanding 208.00M
Short interest —
Earnings date Nov 10, 2026
Analyst target 60.10
Profit margin 18.38%
No recent coverage in the 4Search index.
From articles in the 4Search news index.
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing's syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for…
Sector Healthcare
Industry Drug Manufacturers - General
Chief executive Robert Koremans M.D.
Employees 4,700
Headquarters Milan, MI, Italy
Buy 8 analysts
2 2 4 0 0 12-month price target 60.10 +13.50%
Low 51.30 Current 52.95 High 71.00
Wall Street analyst consensus. Not a recommendation.
Earnings
Next report: Tue, Nov 10, 2026
Net margin 16.7% (Q2 '26) Prices may be delayed up to 15 min. Not investment advice.
Not eligible for Gainers, Losers, Most active (U.S. stocks worth $2 billion or more only).
Not eligible for Small-cap gainers, Aggressive small caps (U.S. stocks worth under $2 billion only).
Not eligible for Growth tech (U.S. technology stocks only).
Not eligible for Undervalued large caps (U.S. stocks worth $10 billion or more only).
A day counts when it ranked in the top 25 of a list. Tracked since Oct 10, 2026.
Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use .